ArticleJournal of vascular surgery cases and innovative techniques2025
RevCore thrombectomy device effectively restores venous stent patency by treating iliofemoral caval in-stent restenosis.
Article in Journal of vascular surgery cases and innovative techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal Thrombectomy for Complex Venous Occlusions and In-Stent Thrombosis.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experience with the RevCore mechanical thrombectomy device in a series of 40 patients is described. The device was employed in the treatment of symptomatic in-stent restenosis (ISR) in iliofemoral caval venous stents in these patients. Computed tomography venography was performed preoperatively to differentiate ISR from stent compression in all patients who underwent intervention. All patients were treated in a single session with a mean estimated blood loss of <10 mL with an average operative time of <30 minutes. Alteplase was not used in any patient. All patients were discharged home the same day. Resolution of ≥50% ISR at the end of the procedure on intravascular ultrasound examination was noted in all patients. Symptom resolution was noted in all patients after the use of the RevCore device. No clinical perioperative pulmonary embolism was observed. Only one patient (2.5%) required reintervention during the follow-up period (range, 2-24 months).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.